Will Transition to Accomplished Commercial and Operational Medtech Veteran Charles Mckhann AUSTIN, TX / ACCESSWIRE / February 8, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, announced today a planned CEO change. Effective March 1, 2021, Charles (Chas) McKhann will become CEO and a member of the Board of...
Read more
Targets for 2021 include dermal injector commercial launch, new partnerships, new innovation initiatives, and launch of more clinical testing VANCOUVER, BC / ACCESSWIRE / February 8, 2021 / RepliCel Life Sciences Inc. (TSXV:RP)(OTC PINK:REPCF)(FRA:P6P2) (“RepliCel” or the “Company”), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to provide an update to shareholders...
Read moreVANCOUVER, BC / ACCESSWIRE / February 5, 2021 / EastWest Bioscience (the "Company" or "EastWest") (TSXV:EAST) announces, subject to its stock option plan, the grant of 1,720,000 stock options to certain directors, officers, employees and consultants issued pursuant to the Company's stock option plan. The options vest over a 2 year period, are exercisable at a price of $0.05 per share and expire in February 2024. The...
Read more
ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / February 5, 2021 / Molecular Partners AG (SIX:MOLN) Research & Development Highlights: Virology: Initiated and rapidly advanced COVID-19 antiviral program into the clinic; secured collaboration with Novartis for co-development of multi-specific candidates MP0420 (ensovibep) and MP0423, including options for global commercialization; terms included potential total cash consideration of...
Read more
New study shows that Molecular Partners' tri-specific antiviral DARPin® candidates, ensovibep (MP0420) and the Company's preclinical candidate, MP0423, remain therapeutically active against the known mutations of SARS-CoV-2 including those present in the United Kingdom (UK) and South Africa (SA) variants Phase 2/3 clinical studies of ensovibep planned to initiate in Q2 2021 ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE /...
Read more
VANCOUVER, BC / ACCESSWIRE / February 3, 2021 / Experion Holdings Ltd. (the "Company" or "Experion") (TSXV:EXP)(OTCQB:EXPFF)(FRANKFURT:MB31) is pleased to share a market update, outlook for 2021 and to announce Mr. Jarrett Malnarich, Experion's CEO will be presenting at the live webcast investor conference this Thursday, February 4, 2021. As we enter 2021, Experion and its brand, Citizen Stash, have now been serving...
Read more
JUPITER, FL / ACCESSWIRE / February 3, 2021 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs, and improve the performance of vaccines, drugs and other biological products at flexible commercial scales, today announced that Ronen Tchelet, PhD, Dyadic's Chief Scientific...
Read more
DURHAM, NC / ACCESSWIRE / February 3, 2021 / GeneCentric Therapeutics, a company making precision medicine more precise, announced today the appointment of Philippe Chemla, PhD, MBA, as Chief Business Officer. Dr. Chemla has extensive experience across multiple areas of life sciences research and development, with a focus on strategic collaborations and business development. "Philippe brings a strong track record of senior management and...
Read more
CHEYENNE, WY / ACCESSWIRE / February 3, 2021 / MJ Biotech, Inc. (OTC PINK:MJTV), is pleased to announce, samples of the Covid-19 Rapid Test Kits have been shipped and will arrive this week in The Republic of Namibia. in Southern Africa. Our MJTV Africa sales representative, Invest Africa Global, LLC (IAG), is now expected to finalize the initial orders for the Covid-19 Rapid Test Kits. Having the samples delivered to the potential buyers...
Read more
OTTAWA, ON / ACCESSWIRE / February 3, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF), a biopharmaceutical pioneer in immunomodulator drug discovery and development announced today the creation of a wholly-owned subsidiary called ENJOUCA™. Jurisdictions differ greatly in terms of regulatory requirements surrounding medical cannabis, which means that in some territories,...
Read morePENTICTON, BC / ACCESSWIRE / February 2, 2021 / Ms. Ciska Asriel issues this press release pursuant to Part 3 - Early Warning Requirements of National Instrument 62-103 with respect to EastWest Bioscience Inc. ("EastWest") Ms. Ciska Asriel, the COO and CFO of EastWest has directly acquired 500,000 common shares by a series of purchases through the facilities of the TSX Venture Exchange at $0.05 per share on February 2, 2021 (the...
Read more
TORONTO, ON / ACCESSWIRE / February 2, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, has secured a commitment of up to C$14 million (US$ 11 million) from the Government of Canada to complete the Phase 2 portion of a Phase 2/Phase 3 clinical study of its investigational drug, EB05, for the treatment of hospitalized COVID-19 patients. The funding will also help fund certain pre-clinical research intended to...
Read more
JUPITER, FL / ACCESSWIRE / February 2, 2021 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs, and improve the performance of vaccines, drugs and other biological products at flexible commercial scales, today announced a fully funded collaboration with TurtleTree Scientific to...
Read more
BURBANK, CA / ACCESSWIRE / February 2, 2021 / Medolife Rx, Inc., ("Medolife") a majority owned subsidiary of Quanta, Inc. (OTC PINK:QNTA), announced today that it began major distribution of its Quanta Muscle Rub™ products in Canada in collaboration with Better Health Sciences, Inc. During a pilot sale campaign, Better Health Sciences received exceptionally positive feedback from its customers on the Quanta Muscle Rub™, a...
Read more
Havn Life to supply psychedelic compounds for clinical trials launched by neuroscience and technology leader HealthTech Connex VANCOUVER, BC / ACCESSWIRE / February 2, 2021 / Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (the "Company" or "Havn Life"), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is pleased to announce a...
Read more
- Positive preclinical data demonstrating that a single dose of [212Pb]-VMT01 significantly enhanced response to immune checkpoint inhibitors relative to checkpoint inhibitor treatment alone with a 43% rate of complete response in a B16 melanoma tumor model in mice - - Company plans to advance its VMT01 program into Phase 1 imaging study, to be followed by Phase 1/2a therapy study for the treatment of metastatic melanoma - CORALVILLE, IA /...
Read more
CAPE TOWN, SA / ACCESSWIRE / February 1, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("Wuhan'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce today that the Company has released its financial results for the full year ended December 31, 2019 and 2020 by posting on the OTC Market website. Please visit www.otcmarkets.com to...
Read more
Company begins process of identifying conserved/immutable target sites on SARS-CoV-2 (the CoronaVirus) and other developments COLLEGE STATION, TX / ACCESSWIRE / February 1, 2021 / Enzolytics, Inc. (OTC PINK:ENZC)(the "Company") today announced it has identified seven additional conserved, expectedly immutable sites on the HIV virus against which it plans to produce targeted anti-HIV monoclonal antibodies. The Company's primary...
Read more
CHEYENNE, WY / ACCESSWIRE / February 1, 2021 / MJ Biotech, Inc. (OTC PINK:MJTV), is pleased to announce, its wholly-owned Subsidiary, New England Biotech's partner Genesis Botanical, signed its first contract with a Maine farmer to provide 40 acres of hemp biomass for extraction for the 2021 farming season. Company executives met with the farmer and his team at their indoor facility to discuss and advise on the different varieties of...
Read more
VANCOUVER, BC / ACCESSWIRE / January 29, 2021 / NeutriSci International Inc. ("NeutriSci" or the "Company") (TSXV:NU)(OTCQB:NRXCF)(FRANKFURT:1N9), an innovative technology company developing products for the nutraceutical industry, is pleased to announce that it has closed a non-brokered private placement (the "Placement") in which it raised gross proceeds of $370,050. This Placement consisted of 2,467,000 units...
Read more
